Who
GOLDMAN SACHS GROUP INC
Other role
Company insider
Files Form 4 as: Other, Attovia Therapeutics; 10% owner, Aperture AC; 10% owner, QVC Group, Inc. 8.0% Fixed Rate Cumulative Redeemable Preferred; 10% owner, Sweetgreen; 10% owner, Soho House & Co; 10% owner, Inflection Point Acquisition Corp. IV; 10% owner, Mirion Technologies; 10% owner, Sterling Check.
In numbers
- Trades disclosed
- 887
- Buys
- 182
- Sells
- 210
- Bought
- $144.3M
- Sold
- $688.3M
- Companies
- 62
- Companies where not an officer
- 62
- First trade
- 30 Jan 2006
- Last trade
- 6 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 28 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,957,134 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —478,498 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.5M500,000 at $17.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,181,830 at $0.00 | filing |
| 6 Aug 2026filed 13 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,445,275 at $0.00 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.8M85,000 at $21.00 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,211100 at $22.11 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K753 at $21.97 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K672 at $22.02 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $154K6,970 at $22.03 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,808400 at $22.02 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K1,180 at $21.84 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K1,040 at $22.05 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,252300 at $20.84 | filing |
| 5 Aug 2026filed 28 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,649443 at $21.78 | filing |
The newest 500 lines are listed; the numbers count every line.
News
GS - The Goldman Sachs Group Inc Analysismorningstar.com · 19 Sep 2026Critical Comparison: NextTrip (NASDAQ:NTRP) versus Sweetgreen (NYSE:SG)SG · themarketsdaily.com · 21 Oct 2026Traders Purchase Large Volume of Sweetgreen Call Options (NYSE:SG)SG · dailypolitical.com · 19 Oct 2026
1 headline in the last 90 days name GOLDMAN SACHS GROUP INC; 2 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.